{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T05:26:11Z","timestamp":1768454771994,"version":"3.49.0"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100007108","name":"George Washington University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100003157","name":"Myasthenia Gravis Foundation of America","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100003157","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Neurology"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1016\/j.expneurol.2014.12.022","type":"journal-article","created":{"date-parts":[[2015,1,14]],"date-time":"2015-01-14T03:45:54Z","timestamp":1421207154000},"page":"78-81","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["How clinical trials of myasthenia gravis can inform pre-clinical drug development"],"prefix":"10.1016","volume":"270","author":[{"given":"Anna","family":"Rostedt Punga","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henry J.","family":"Kaminski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David P.","family":"Richman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Benatar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.expneurol.2014.12.022_bb0005","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s00005-011-0158-6","article-title":"Acetylcholine receptor-induced experimental myasthenia gravis: what have we learned from animal models after three decades?","volume":"60","author":"Baggi","year":"2012","journal-title":"Arch. Immunol. Ther. Exp. (Warsz)"},{"key":"10.1016\/j.expneurol.2014.12.022_bb0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.nbd.2006.12.015","article-title":"Lost in translation: treatment trials in the SOD1 mouse and in human ALS","volume":"26","author":"Benatar","year":"2007","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.expneurol.2014.12.022_bb0015","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1002\/mus.23330","article-title":"Recommendations for myasthenia gravis clinical trials","volume":"45","author":"Benatar","year":"2012","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.expneurol.2014.12.022_bb0025","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jaut.2013.12.011","article-title":"Myasthenia gravis: a comprehensive review of immune dysregulation and etiological mechanisms","volume":"52C","author":"Berrih-Aknin","year":"2014","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.expneurol.2014.12.022_bb0020","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jaut.2014.01.003","article-title":"Diagnostic and clinical classification of autoimmune myasthenia gravis","volume":"48\u201349","author":"Berrih-Aknin","year":"2014","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.expneurol.2014.12.022_bb0030","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1006\/clim.1999.4807","article-title":"Animal models of myasthenia gravis","volume":"94","author":"Christadoss","year":"2000","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.expneurol.2014.12.022_bb0035","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/509282a","article-title":"Policy: NIH to balance sex in cell and animal studies","volume":"509","author":"Clayton","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.expneurol.2014.12.022_bb0040","series-title":"Transparent Reporting of Trials","author":"CONSORT","year":"2014"},{"key":"10.1016\/j.expneurol.2014.12.022_bb0045","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1046\/j.1365-2249.1997.d01-881.x","article-title":"Age- and sex-related resistance to chronic experimental autoimmune myasthenia gravis (EAMG) in Brown Norway rats","volume":"107","author":"Hoedemaekers","year":"1997","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.expneurol.2014.12.022_bb0050","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/mus.23839","article-title":"A randomized, double-blind, placebo-controlled Phase II study of eculizumab in patients with refractory generalized myasthenia gravis","volume":"48","author":"Howard","year":"2013","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.expneurol.2014.12.022_bb0055","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1212\/WNL.55.1.16","article-title":"Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America","volume":"55","author":"Jaretzki","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.expneurol.2014.12.022_bb0060","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1749-6632.2012.06787.x","article-title":"Biomarker development for myasthenia gravis","volume":"1275","author":"Kaminski","year":"2012","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.expneurol.2014.12.022_bb0065","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/j.1365-3083.1995.tb03648.x","article-title":"Mechanisms by which the I-ABM12 mutation influences susceptibility to experimental myasthenia gravis: a study in homozygous and heterozygous mice","volume":"42","author":"Karachunski","year":"1995","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/j.expneurol.2014.12.022_bb0070","doi-asserted-by":"crossref","first-page":"e102231","DOI":"10.1371\/journal.pone.0102231","article-title":"Survivin as a potential mediator to support autoreactive cell survival in myasthenia gravis: a human and animal model study","volume":"9","author":"Kusner","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.expneurol.2014.12.022_bb0075","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/nature11556","article-title":"A call for transparent reporting to optimize the predictive value of preclinical research","volume":"490","author":"Landis","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.expneurol.2014.12.022_bb0080","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1177\/0962280207082719","volume":"17","author":"Lassere","year":"2008","journal-title":"Stat. Methods Med. Res."},{"key":"10.1016\/j.expneurol.2014.12.022_bb0085","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1155\/2002\/438745","article-title":"Biomarkers and surrogate endpoints: how and when might they impact drug development?","volume":"18","author":"Lathia","year":"2002","journal-title":"Dis. Markers"},{"key":"10.1016\/j.expneurol.2014.12.022_bb0090","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1080\/17482960701856300","article-title":"Design, power, and interpretation of studies in the standard murine model of ALS","volume":"9","author":"Scott","year":"2008","journal-title":"Amyotroph. Lateral Scler."},{"key":"10.1016\/j.expneurol.2014.12.022_bb0095","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1212\/WNL.57.11.2139","article-title":"Spontaneous remission in canine myasthenia gravis: implications for assessing human MG therapies","volume":"57","author":"Shelton","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.expneurol.2014.12.022_bb0100","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/cei.12217","article-title":"Myasthenia gravis: an update for the clinician","volume":"175","author":"Sieb","year":"2014","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.expneurol.2014.12.022_bb0105","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1002\/mus.21142","article-title":"Comparison of outcome measures from a trial of mycophenolate mofetil in myasthenia gravis","volume":"38","author":"Wolfe","year":"2008","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.expneurol.2014.12.022_bb0110","doi-asserted-by":"crossref","first-page":"8562","DOI":"10.4049\/jimmunol.179.12.8562","article-title":"Anti-C5 antibody treatment ameliorates weakness in experimentally acquired myasthenia gravis","volume":"179","author":"Zhou","year":"2007","journal-title":"J. Immunol."}],"container-title":["Experimental Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014488615000072?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014488615000072?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,4,3]],"date-time":"2021-04-03T14:51:27Z","timestamp":1617461487000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014488615000072"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8]]},"references-count":22,"alternative-id":["S0014488615000072"],"URL":"https:\/\/doi.org\/10.1016\/j.expneurol.2014.12.022","relation":{},"ISSN":["0014-4886"],"issn-type":[{"value":"0014-4886","type":"print"}],"subject":[],"published":{"date-parts":[[2015,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"How clinical trials of myasthenia gravis can inform pre-clinical drug development","name":"articletitle","label":"Article Title"},{"value":"Experimental Neurology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.expneurol.2014.12.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}